title: Toll-like receptor 2/6-dependent stimulation of mesenchymal stem cells promotes angiogenesis by paracrine factors.
abstract: Reconstruction of critical size bone defects represents a major challenge in orthopaedic surgery. Insufficient angiogenesis is a limiting factor for engraftment of large-scale tissue transplants. Transplantation or stimulation of local mesenchymal stem cells (MSCs) represents a potential solution to enhance angiogenesis. We recently identified angiogenic properties for the Toll-like receptor (TLR) 2/6 agonist MALP-2 and now investigated if MALP-2 could be used to stimulate MSCs in order to promote angiogenesis in vitro and in vivo. Human MSCs from the bone marrow of healthy subjects were isolated, cultured and expanded in vitro and were shown to be positive for mesenchymal stem cells markers as well as for the MALP-2 receptors TLR2 and TLR6. MALP-2 directly enhanced migration but not proliferation of human MSCs. Conditioned medium from MALP-2 stimulated MSCs significantly increased proliferation, migration and tube formation of endothelial cells. Analysis of the conditioned medium from MSCs revealed that MALP-2 stimulation enhanced the secretion of several chemokines and growth factors including vascular endothelial growth factors (VEGF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Finally, we studied MALP-2 effects on MSCs in a sheep model of tissue engineering in vivo. Therefore, MSCs were isolated from the iliac crest of black head sheep and co-cultivated with MALP-2 ex vivo. Implantation of autologous MSCs within a scaffold cylinder into the M. latissimus dorsi significantly enhanced vessel density of these constructs after 6 months. We here present the first evidence that TLR2/6-dependent stimulation of MSCs promotes angiogenesis in vitro and in vivo offering a novel strategy for therapeutic angiogenesis, e.g., for tissue engineering of bone.
authors.affiliation: Trauma Department, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.petri.maximilian@mh-hannover.de.
authors.forename: K
authors.initials: K
authors.lastname: Grote
authors.forename: M
authors.initials: M
authors.lastname: Petri
authors.forename: C
authors.initials: C
authors.lastname: Liu
authors.forename: P
authors.initials: P
authors.lastname: Jehn
authors.forename: S
authors.initials: S
authors.lastname: Spalthoff
authors.forename: H
authors.initials: H
authors.lastname: Kokemüller
authors.forename: M
authors.initials: M
authors.lastname: Luchtefeld
authors.forename: T
authors.initials: T
authors.lastname: Tschernig
authors.forename: C
authors.initials: C
authors.lastname: Krettek
authors.forename: C
authors.initials: C
authors.lastname: Haasper
authors.forename: M
authors.initials: M
authors.lastname: Jagodzinski
mesh_terms: D000818:Animals; D002465:Cell Movement; D049109:Cell Proliferation; D018925:Chemokines / Q000235:genetics / Q000378:metabolism; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism; D055666:Lipopeptides / Q000494:pharmacology; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000378:metabolism / Q000502:physiology*; D018482:Muscle, Skeletal / Q000502:physiology; D018919:Neovascularization, Physiologic; D019899:Paracrine Communication; D012038:Regeneration; D012756:Sheep; D023822:Tissue Engineering; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051216:Toll-Like Receptor 6 / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D018925:Chemokines; D036341:Intercellular Signaling Peptides and Proteins; D055666:Lipopeptides; C495342:TLR2 protein, human; D051195:Toll-Like Receptor 2; D051216:Toll-Like Receptor 6; C106335:macrophage stimulatory lipopeptide 2